Nasus Pharma Reports $4.3M Cash, NS002 Phase 2 Spurs Q4 2026 Pivotal Study
NS002 Phase 2 topline data showed statistically significant faster time to therapeutic threshold and higher epinephrine absorption versus EpiPen, driving a pivotal study to start in Q4 2026 with a readout by Q1 2027. The company ended 2025 with $4.3M cash, raised via $15M private placement to fund operations into mid-2027.
1. NS002 Phase 2 Results and Pivotal Plans
Nasus Pharma’s intranasal epinephrine candidate NS002 delivered statistically significant improvements in time to therapeutic threshold (T100) and a higher proportion of participants reaching therapeutic levels within minutes, compared with EpiPen. These results underpin a pivotal trial slated to begin in Q4 2026, with topline readout expected in Q1 2027, targeting a potential NDA submission thereafter.
2. Financial Position and Funding Runway
As of December 31, 2025, the company held $4.3 million in cash, boosted by a $15 million private placement closed in February 2026. This funding is projected to support operations through mid-2027, covering the NS002 pivotal study and early clinical milestones for other pipeline candidates.
3. Early-Stage Pipeline Advancement
Beyond NS002, Nasus is advancing three additional intranasal powder programs: NS003 (ondansetron for chemotherapy-induced nausea and vomiting), NS004 (metabolic disorders) and NS005 (cardiovascular diseases). First-in-human Phase 1 studies for NS003 and NS004 are expected to commence in H2 2026, expanding the company’s PBI technology into high-value therapeutic areas.